This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Third View: Discussing recent approval for first biologic treatment of COPD with Dupixent.
Ticker(s): REGNWho's the expert?
Institution: Imperial College London
- Research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases.
- Involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases.
- Amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years.
Interview GoalThis conversation will focus on the treatment of COPD and the recent approval of the use of Dupixent for patients with COPD.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
